Almac Diagnostics, part of the Northern Ireland-based Almac Group, has begun collaborating with Illumina to establish a framework for the development of next-generation sequencing (NGS)-based companion diagnostic assays.

The collaboration enables Almac to develop next-generation sequencing (NGS) assays using the Illumina MiSeqDx instrument, the first FDA-cleared IVD NGS system designed specifically for the clinical laboratory environment.

Almac offers significant expertise in the development and delivery of multiplex RNA and DNA based tests and currently partners with a number of major biopharmaceutical companies to assist with companion diagnostic development. The collaboration with Illumina serves to provide an additional platform for delivery of complex assays expanding the options available to Almac partners.